Shares of healthcare test kits provider Lucira Health (NASDAQ:LHDX) are rallying today after the U.S. Food and Drug Administration (FDA) authorized the emergency use of the company’s Lucira COVID-19 & Flu home test.
The molecular test is now the first at-home combination for the two indications as well as the first Flu test for over-the-counter use at home providing results in about 30 minutes with only one nasal swab.
Only days ago, Lucira announced a Chapter 11 bankruptcy filing and is now looking for a partner to resume manufacturing and development of more home diagnostic products.
Despite gaining over 371% in the pre-market session today, LHDX shares are down over 90% over the past year.
Read full Disclosure
